Biocon forecasts stronger second half of FY27 with multiple growth drivers despite Q2 profit decline
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Biocon expects a stronger second half of FY27 after reporting a 52% profit decline on Wednesday.
- ✓CEO Shreehas Tambe said, "We've always said the second half of the year is going to be stronger for us than the first half." New biosimilar launches and rising insulin sales should drive growth.
Story at a Glance
- Category
- MARKET
- Reported By
- Economic Times
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Biocon anticipates a robust second half of FY27, supported by several key product launches and increasing insulin sales. The company noted a 52% decline in consolidated net profit, attributed to delayed shipments affecting quarterly revenue. Ustekinumab and Aflibercept biosimilars are projected to boost sales in the US market significantly. Additionally, the launch of Pertuzumab in Europe and Brazil is expected to generate substantial revenue.
Mumbai: Biocon expects a stronger second half of FY27, driven by four growth engines, its Ustekinumab and Aflibercept biosimilars in the US, the upcoming launch of Pertuzumab in Europe and Brazil, and rising demand for insulin, Biocon CEO and Managing Director Shreehas Tambe said.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Economic Times
Read the full, original unfiltered story directly on the publisher's portal.